



James C. Greenwood
President & CEO

June 3, 2015

The Honorable John Shimkus
U.S. House of Representatives
2217 Rayburn House Office Building
Washington, D.C. 20515

The Honorable Gene Green
U.S. House of Representatives
2470 Rayburn House Office Building
Washington, D.C. 20515

Dear Representative Shimkus and Representative Green:

The Biotechnology Industry Organization (BIO), whose 1100 members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products, appreciates your active leadership and commitment to developing antibacterial and antifungal drugs intended to treat serious or life-threatening diseases. As such, we strongly support your introduction of the ADAPT Act

Like you, BIO is committed to attacking new drug-resistant strains of bacteria and developing the next generation of treatments to do so. The ADAPT Act will create the necessary pathways for prompt approval of these new drugs, and ultimately save lives. It also provides for an assessment of the program and a process for determining whether expansion of this pathway would benefit the public health which is sound policy.

Additionally, strengthening resistance monitoring by the Centers for Disease Control and making this data publically available, as the ADAPT Act does, greatly serves the public interest.

BIO supports and urges prompt passage of the ADAPT Act. We look forward to working with you to move this bill through the House without delay.

Sincerely,

A handwritten signature in black ink that reads "Jim Greenwood". The signature is fluid and cursive, with a large loop at the beginning.

James C. Greenwood
President and CEO